Development of A Predictive Radiomics Model for Lymph Node Metastases in Pre-surgical CT-based Stage IA Non-Small Cell Lung Cancer

Lung cancer has been identified as the leading cause of cancer-related deaths worldwide and one of the most common malignancies in China [1]. More and more non-small cell lung cancer (NSCLC) patients have been observed in the screening projects for detection of early stage lung cancer with the use of low dose computed tomography (CT) [2]. Accurate imaging for evaluation of the Lymph Node Metastases (LNM) could affect the treatment of these patients [3]. Many imaging modalities such as CT, Magnetic Resonance Imaging (MRI), Positron Emission Tomography-CT (PET-CT), as well as other diagnostic techniques like ultrasound-guided biopsy, and thoracoscopy have been applied to evaluate LNM in the NSCLC patients [4,5].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Publication date: Available online 13 December 2019Source: Cancer GeneticsAuthor(s): Gokce A Toruner, Zhenya Tang, Guilin Tang, L. Jeffrey Medeiros, Shimin HuAbstractALK FISH assay guides clinical decision to initiate therapy with ALK inhibitors in patients with stage IV non-small cells lung cancer (NSCLC). In this single institution retrospective study, we investigated the association between the strength of ALK positivity and progression-free survival (PFS) We screened 4,829 patients tested for ALK rearrangement by FISH from 01/06/2012 to 06/30/2018 and included 66 stage IV NSCLC ALK positive patients, who were ALK inhib...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
Authors: Reck M, Shankar G, Lee A, Coleman S, McCleland M, Papadimitrakopoulou VA, Socinski MA, Sandler A Abstract Introduction: Cancer immunotherapy has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). However, specific patient groups (e.g. patients with activating epidermal growth factor receptor [EGFR] mutations) do not appear to derive benefit from immune checkpoint inhibitor (ICI) monotherapy. Combining ICIs, such as atezolizumab, with chemotherapy and/or targeted therapies may help to address this unmet need.Areas covered: Atezolizumab is an anti-program...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
In this study we set out to evaluate the biological relevance and serum biomarker potential of citrullinated vimentin (VICM) and non-citrullinated vimentin (VIM) in non-small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD). METHODS: A competitive ELISA targeting VIM was developed and quantified in serum from patients with NSCLC and COPD. VIM was compared with levels of VICM in the same indications. RESULTS: VIM was significantly increased in NSCLC (n = 100) compared to healthy controls (n = 67) in two independent cohorts (p = 0.0003 and p
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M Abstract UL16-binding protein (ULBP) 1-6 and MHC class I chain-related molecule A and B (MICA/B) are NK group 2, member D (NKG2D) ligands, which are specifically expressed in infected or transformed cells and are recognized by NK cells via NKG2D-NKG2D ligand interactions. We previously reported that MICA/B overexpression predicted improved clinical outcomes in patients with resected non-small cell lung cancer (NSCLC). However, the clinicopathological features and prognostic significance of ULBPs in NSCLC remain unclear. Here,ULBP1-6 expression was e...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Conclusion: The TIMP3 silencing observed in the NLNT and its negative correlation with presurgical expression of miR-20a (from serum exosomes), suggest that miRs can influence ECM remodeling at a distance from the center of the lesion. The miRs expression pattern in serum obtained before surgery significantly differs between AC and SCC subtypes. Moreover, decreased TIMP3 expression in NLNT (in SCC group) negatively correlates with the amount of tobacco smoked in a lifetime in PY.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Non Small Cell Lung Cancer Interventions:   Drug: anti-PD-1 or anti-PD-L1;   Drug: EGFR-TKI, ALK inhibitor, ROS1 inhibitor;   Drug: investigator decided Sponsor:   Shanghai Chest Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We examined LATS2 protein expression by immunohistochemistry in 184 resected NSCLC specimens using tissue microarrays. Low LATS2 expression was significantly related to disease recurrence (p = 0.047). In survival analysis, the low LATS2 expression group showed a statistically poorer overall survival (OS) (p = 0.004) and disease-free survival (DFS) (p = 0.014) than the high expression group. In multivariate analysis, downregulated LATS2 expression in NSCLC could be an independent prognostic factor of poor OS and DFS. Furthermore, we evaluated the prognostic signifi...
Source: Polish Journal of Pathology - Category: Pathology Tags: Pol J Pathol Source Type: research
In this study, we aimed to investigate the prognostic significance of CD63 expression in non-small cell lung cancer (NSCLC). CD63 expression was evaluated in 133 cases of NSCLC via immunohistochemical staining using tissue microarray blocks. We assessed the relationship between CD63 expression and clinicopathological characteristics, as well as the prognostic significance of CD63 expression in NSCLC. CD63 expression was significantly correlated with patient gender (p 
Source: Polish Journal of Pathology - Category: Pathology Tags: Pol J Pathol Source Type: research
In conclusion, the present study demonstrated that PCAT19 negatively regulates the p53 tumor-suppression pathway, promoting cancer cell proliferation in patients with NSCLC. PMID: 31819778 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
More News: Cancer | Cancer & Oncology | China Health | CT Scan | Lung Cancer | Men | MRI Scan | Non-Small Cell Lung Cancer | PET Scan | Ultrasound